
Aktis Oncology
Developer of a targeted radiopharmaceutical designed to treat a broad range of solid tumour cancers. The company's radiopharmaceuticals generate cell-targeting agents with ideal properties for alpha r...
Valuation
$0
Share Price
N/A
Total Raised
$336M
Last Round
N/A